SCHEMBL4682969

SCHEMBL4682969

Cc1ccc(C(=O)NC(O)C(F)(F)F)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.70
SMN1; SMN2 Q16637 4/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ALDH1A1 P00352 4/20 0.52
GAA P10253 1/20 0.52
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
LMNA P02545 4/20 0.49
MLYCD O95822 2/20 0.49
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
TP53 P04637 1/20 0.46
MAPT P10636 3/20 0.44
TRPA1 O75762 1/20 0.44
CA2 P00918 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.42
MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6559620 0.84 CES2 (0.56) HPGDMLYCDNPC1RAB9A
SCHEMBL4683894 0.82 HTT (0.53) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL1923460 0.82 CA12 (0.54) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4679490 0.82 HPGD (1.00) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL6560658 0.81 LMNA (0.50) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4682046 0.81 SMN1; SMN2 (0.64) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL12093587 0.77 HPGD (0.65) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL178370 0.75 MEN1 (0.66) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4682520 0.74 HPGD (0.48) HPGDSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL24386393 0.74 HPGD (0.61) HPGDSMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392655-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2008-07-16 EP disclosed
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
WO-2002062762-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO disclosed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP disclosed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US disclosed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028836-A1 Potassium channel openers KCNJ2, KCNJ11, KCNJ1 HPGD 1616/4885SMN1; SMN2 650/4885MEN1 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.